Mesoblast plans half-year 2025 results webcast

Mesoblast Limited is informing investors that it will host a webcast to discuss operational highlights and financial results for the half year ended December 31, 2025.

Rhea-AI Filing Summary

Mesoblast Limited is informing investors that it will host a webcast to discuss operational highlights and financial results for the half year ended December 31, 2025. The webcast is scheduled for 5:00 p.m. EST on Thursday, February 26, and 9:00 a.m. AEDT on Friday, February 27, 2026, and can be accessed online at the provided webcast link.

Mesoblast describes itself as a world leader in developing allogeneic, off-the-shelf cellular medicines for severe inflammatory conditions. Its therapy Ryoncil® (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients is stated to be the first FDA-approved mesenchymal stromal cell therapy, and the company is advancing additional indications and partnerships globally.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Mesoblast (MESO) announcing in this Form 6-K filing?

Mesoblast is announcing a webcast to discuss operational highlights and financial results for the half year ended December 31, 2025. The webcast details, access link, and replay information are provided for investors and other interested stakeholders.

When will Mesoblast’s half-year 2025 financial results webcast take place?

The webcast will take place at 5:00 p.m. EST on Thursday, February 26, and 9:00 a.m. AEDT on Friday, February 27, 2026. These times accommodate audiences in both North America and Australia for the half-year results discussion.

How can investors access Mesoblast’s upcoming financial results webcast?

Investors can access the webcast via the link https://webcast.openbriefing.com/msb-hyr-2026/. An archived version will also be available on the Investor page of Mesoblast’s website, www.mesoblast.com, allowing viewers to watch the presentation after the live event.

What financial period will Mesoblast cover in the announced webcast?

The webcast will cover Mesoblast’s operational highlights and financial results for the half year ended December 31, 2025. This period provides an interim update on the company’s performance and activities across its cell therapy programs and partnerships.

What is Mesoblast’s Ryoncil therapy mentioned in the filing?

Ryoncil (remestemcel-L-rknd) is Mesoblast’s allogeneic mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in pediatric patients. It is described as the first FDA-approved mesenchymal stromal cell therapy, with development ongoing for additional inflammatory indications.

In which markets is Mesoblast listed and where does it operate?

Mesoblast is listed on the Australian Securities Exchange under the code MSB and on Nasdaq under the symbol MESO. The company has locations in Australia, the United States, and Singapore, supporting its global cell therapy development and manufacturing activities.

What therapeutic areas is Mesoblast focusing on beyond graft versus host disease?

Beyond steroid-refractory acute graft versus host disease, Mesoblast is developing remestemcel-L for additional inflammatory diseases and rexlemestrocel-L for heart failure and chronic low back pain. These programs build on its proprietary allogeneic stromal cell technology platforms and global partnerships.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 06:06 AM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of February 2026

Commission File Number 001-37626

Mesoblast Limited

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Australia
(Jurisdiction of incorporation or organization)

Silviu Itescu

Chief Executive Officer and Executive Director

Level 38

55 Collins Street

Melbourne 3000

Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F ☑ Form 40-F ☐

INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K

On February 20, 2026, Mesoblast Limited filed with the Australian Securities Exchange a new release announcement, which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

Mesoblast Limited

/s/ Paul Hughes

Paul Hughes

Company Secretary

Dated: February 23, 2026

INDEX TO EXHIBITS

Item
99.1						Press release of Mesoblast Ltd, dated February 20, 2026.

MESOBLAST FINANCIAL RESULTS AND CORPORATE UPDATE WEBCAST New York, USA: February 20 and Melbourne, Australia: February 20, 2026: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the half year ended December 31, 2025. The webcast will begin at 5.00pm EST, Thursday, February 26; 9.00am AEDT, Friday, February 27, 2026. It can be accessed via: https://webcast.openbriefing.com/msb-hyr-2026/ The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com. Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets. About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast Release authorized by the Chief Executive.

For more information, please contact: Corporate Communications / Investors Paul Hughes T: +61 3 9639 6036 Media – Global Media – Australia Rubenstein BlueDot Media Caroline Nelson Steve Dabkowski T: +1 703 489 3037 T: +61 419 880 486 E: cnelson@rubenstein.com E: steve@bluedot.net.au

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 4.2 KB